Open AccessUrokinase and tissue plasminogen activators and their inhibitor for thyroid diseases
Author(s) -
Н. Е. Кушлинский,
И. А. Казанцева,
Е. С. Герштейн,
T Yu Kharitidi,
L. T. Lyakina
Publication year - 2004
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl11411
Subject(s) - urokinase , thyroid , thyroid adenoma , thyroid cancer , adenoma , goiter , medicine , endocrinology , cancer , pathology , chemistry
The results of a comparative study of the level of the components of the plasminogen activation system - и Pa, tPA, and PAI-1 in the tissues of cancer and benign masses of the thyroid are presented. Nineteen patients with nodal colloidal goiter (NCG) with adenomatosis, 43 patients with NCG without adenomatosis, 9patients with diffuse toxic goiter (DTG) with adenomatosis, 13 patients without adenomatosis, 18 patients with thyroid adenoma (TA), and 44 patients with thyroid cancer (TC) were examined. The concentrations of the studied proteins were determined by enzyme immunoassay in tissue cytosols. The lowest levels of tPA and the highest values of и PA and PAI-1 were found in the tumors of patients with TC whereas the high values of tPA and the relatively low levels of и PA were typical of benign thyroid hyperplasias and TA. The lowest levels of PAI-1 were detected in patients both with and without DTG. The tissue level of the components of the plasminogen activation system in TC did not virtually depend on the histological features of a tumor, but it significantly correlated with the extent of a process.